WO2009114773A2 - Formulations à libération modifiée des médicaments anti-irritabilité - Google Patents

Formulations à libération modifiée des médicaments anti-irritabilité Download PDF

Info

Publication number
WO2009114773A2
WO2009114773A2 PCT/US2009/037104 US2009037104W WO2009114773A2 WO 2009114773 A2 WO2009114773 A2 WO 2009114773A2 US 2009037104 W US2009037104 W US 2009037104W WO 2009114773 A2 WO2009114773 A2 WO 2009114773A2
Authority
WO
WIPO (PCT)
Prior art keywords
mesalamine
drug
released
polymer
mixture
Prior art date
Application number
PCT/US2009/037104
Other languages
English (en)
Other versions
WO2009114773A3 (fr
Inventor
Subraman Rao Cherukuri
Revanth Babu Mutyala
Venkat N. Ravella
Original Assignee
Capricorn Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capricorn Pharma, Inc. filed Critical Capricorn Pharma, Inc.
Publication of WO2009114773A2 publication Critical patent/WO2009114773A2/fr
Publication of WO2009114773A3 publication Critical patent/WO2009114773A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Definitions

  • the present invention relates to mesalamine compound containing formulations with desired in-vitro and in ⁇ vivo characteristics and associated methods which are simple to formulate and economical to manufacture on a commercial scale. Accordingly, the present invention involves the field of pharmaceutical sciences.
  • Modified release mesalamine formulations are desirable because they are expected to provide prolonged and some times more site-specific therapeutic benefits in the treatment of disorders such as irritable bowel syndrome, Crohn's disease, etc.
  • Examples of various known modified release mesalamine formulations may be found in United States Patent Nos. 5,811,388; 6,004,581; 5,541,170; 5,541,171; and 4,980,173, each of which are incorporated herein by reference.
  • mesalamine has been used for many years as an active agent to treat the foregoing conditions, there has been, to date, no generic mesalamine product on the market that is approved by the FDA as being pharmaceutically equivalent to known brand products ASACOL® or PENTASA®.
  • the dosage form is a capsule.
  • the dosage form is a tablet.
  • the dosage form is a sachet.
  • the amount of mesalamine per dosage form can be, as stated conventionally, from about 200 mg to about 2000 mg, including specific intermediate amounts such as 250mg, 300mg, 400mg, 500mg, 600mg, 750mg, lOOOmg, 1200mg, 1500mg, and 1800mg.
  • These dosage forms provide a dissolution profile such that: about 15% to about 25% of the drug is released by 60 minutes; about 35% to about 45% of the drug is released by 2 hrs; about 70% to about 85% of the drug is released by 4 hrs; and about 95 ⁇ o to about 105% of the drug is released by 8 hrs when dissolution test is performed using pH 7.5 phosphate buffer.
  • these dosage forms provide a dissolution profile such that: about 15% or less of the drug is released by 60 minutes; about 20% to about 35% of the drug is released by 2 hrs; about 40% to about 60% of the drug is released by 4 hrs; and about 75% to about 90% of the drug is released by 8 hrs when dissolution test is performed using pH 6.8 phosphate buffer and simulated intestinal fluid without pancreatin.
  • these dosage forms provide a dissolution profile such that: about 20% to about 45% of the drug is released by 60 minutes; about 35% to about 75% of the drug is released by 2 hrs; about 90% to about 100% of the drug is released by 4 hrs, when dissolution test is performed using pH 1.2 simulated gastric fluid without pepsin.
  • these dosage forms provide a dissolution profile such that: about 3% to about 6% of the drug is released by 60 minutes; about 8% to about 12% of the drug is released by 2 hrs; about 16% to about 20% of the drug is released by 4 hrs; and more than about 25% the drug is released by 8 hrs when dissolution test is performed using pH 4.5 phosphate buffer.
  • the dosage forms may be used to treat irritable bowel syndrome or Crohn's disease, among others.
  • the method comprises the following steps: a) preparing a mixture comprising mesalamine and one or more pharmaceutically acceptable excipients to form a rnesalamine-excipient mixture; b) granulating the mesalamine-excipient mixture in the presence of a water-impermeable polymer to produce mesalamine granulates; c) spheronizing and extruding the mesalamine granulates to produce mesalamine cores, and optionally drying and sieving said cores; d) preparing a dispersion of a water-impermeable polymer, or a water- swellable polymer, or a mixture thereof to produce a coating polymer dispersion; and e) coating said mesalamine cores with said coating polymer dispersion to obtain coated mesalamine cores.
  • the method of making a modified release mesalamine oral dosage form comprises: a) providing an inert core of substantially uniform size; b) providing a mesalamine dispersion and optionally a binder dispersion; c) layering said core with the mesalamine dispersion simultaneously with or after optional layering of said core with the binder dispersion to provide mesalamine core; d) preparing a dispersion of a water-impermeable polymer, or a water- swellable polymer, or a mixture thereof to produce a coating polymer dispersion; and e) coating said mesalamine core with said coating polymer dispersion to obtain a coated mesalamine core.
  • any of the previously described mesalamine cores may be formed into capsules, sachets, or tablets. Capsules and sachets may be obtained by filling empty capsules or filling sachets with any of the aforementioned mesalamine cores. [0015] The mesalamine cores may be formed into tablets by compressing one or more of any of the aforementioned mesalamine coated cores together with optional pharmaceutically acceptable excipients.
  • Tablets may also be formed by the following method: f) mixing said coated mesalamine cores with particles comprising cushioning agents at a ratio of from about 5:95 to about 95:5 to provide a mesalamine compressible mixture; g) compressing said mesalamine compressible mixture into one or more tablets; and, h) optionally, coating said compressed mesalamine tablets with a dispersion of a water- impermeable polymer, or a water-swellable polymer, or a mixture thereof to provide coated compressed mesalamine tablets.
  • the one or more pharmaceutically acceptable excipients may be selected from the group consisting of: microcrystalline cellulose, dibasic calcium phosphate dihydrate, starch, sodium starch glycolate, crospovidone, croscarmellose sodium, magnesium stearate, lactose, maleic acid, colloidal silicon dioxide, talc, and glyceryl behenate, or a mixture thereof.
  • any of the aforementioned excipients or mixtures thereof may be used in combination with any of the other embodiments described herein.
  • the water-impermeable polymer is selected from the group consisting of efhylcellulose, propylcellulose, isopropylcellulose, or a mixture thereof.
  • any of the aforementioned water impermeable polymers or mixtures thereof may be used in combination with any of the other embodiments described herein.
  • the water-swellable polymer is selected from the group consisting of methylcellulose (MC), carboxymethylcellulose (CMC), hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), hydroxyethylcellulose (HEC); polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA); and acrylic acid polymer, methacrylic acid copolymers, ethyl acrylate-methyl methacrylate copolymers, or a mixture thereof.
  • MC methylcellulose
  • CMC carboxymethylcellulose
  • HPC hydroxypropylcellulose
  • HPMC hydroxypropylmethylcellulose
  • HEC hydroxyethylcellulose
  • PVP polyvinylpyrrolidone
  • PVA polyvinyl alcohol
  • acrylic acid polymer methacrylic acid copolymers, ethyl acrylate-methyl methacrylate copolymers, or a mixture thereof.
  • the water-swellable polymer may be a pH-dependent- release polymer such as: anionic polymers of methacrylic acid and methacrylates with a dissolution from pH 5.5 and above (commercially known as Eudragit L-IOO or Eudragit L 30 D-55); anionic polymer of methacrylic acid and methacrylates with dissolution from pH 6.0 to 7.5 (commercially known as Eudragit LlOO and Eudragit S 100): and copolymer of methacrylic acid, methacrylate and methylmethacrylate with dissolution from pH 7.0 (commercially known as Eudragit FS 30 D).
  • anionic polymers of methacrylic acid and methacrylates with a dissolution from pH 5.5 and above commercially known as Eudragit L-IOO or Eudragit L 30 D-55
  • anionic polymer of methacrylic acid and methacrylates with dissolution from pH 6.0 to 7.5 commercially known as Eudragit LlOO and Eudragit S 100
  • cushioning agents are added to the coated mesalamine cores prior to tableting.
  • Cushioning agents are agents that provide flexibility to coated mesalamine cores such that when compressed into a tablet, the coated mesalamine cores substantially retain their structural integrity and do not rupture in a significant way or as a significant fraction of the mesalamine cores.
  • the presence of cushioning agents prevent or minimize the rupture of the coating surrounding the coated mesalamine cores such that no more than about 5% to about 25% of the coated mesalamine leaks out of the formulation prior to its reaching the intended target of action.
  • Examples of cushioning agents include: waxes, fats, lipids, polyoxyethylenes, and gums, among others, or other flexible materials that are used in pharmaceutical formulations.
  • waxes include: carnuba wax, bees wax, sperm whale wax, etc.
  • fats and lipids include: lecithin, hydrogenated vegetable oils, including hydrogenated castor oil, hydrogenated sesame oil, etc.
  • gums include: gum Arabica, xanthan gum, gum Accacia, etc. Typically, these materials are formed into particles or granules of suitable size, such as ranging from about 50 microns to about 1200 microns.
  • the cushioning particles or granules may range from about 5% to about 95% by weight of the mixture comprising cushioning agents and the coated mesalamine cores.
  • any of the aforementioned cushioning agents or mixtures thereof may be used in combination with any of the other embodiments described herein.
  • the method comprises administering the dosage form prepared as above.
  • the invention provides a dosage form of mesal amine prepared according to the methods described herein.
  • the invention provides an article of manufacture comprising mesalamine prepared in accordance with the methods described herein and accompanying labeling and packaging to enable the article of manufacture to be shipped interstate, or to meet other regulatory requirements for commercial sale.
  • a modified release mesalamine oral dosage form comprising: a) a therapeutically effective amount of mesalamine, ranging from about 200mg to about 2000mg per dosage unit, formulated into one or more cores comprising said mesalamine and one or pharmaceutically acceptable excipients; b) a release-modifying coat that substantially overlaps said core, wherein said coat comprises a mixture of a water- impermeable polymer and a water- swellable polymer; c) wherein said dosage form releases said mesalamine in a manner described herein, when measured according to the USP.
  • Fig. 1 is a graphical representation of dissolution testing results of a mesalamine formulation prepared in accordance with Example 2 of the present invention. The dissolution was conducted at pH 1.2 as described in Example 9.
  • Fig. 2 is a graphical representation of dissolution testing results of a mesalamine formulation prepared in accordance with Example 2 of the present invention. The dissolution was conducted at pH 4.5 as described in Example 9.
  • Fig. 3 is a graphical representation of dissolution testing results of a mesalamine formulation prepared in accordance with Example 2 of the present invention. The dissolution was conducted at pH 6.8 as described in Example 9.
  • Fig. 1 is a graphical representation of dissolution testing results of a mesalamine formulation prepared in accordance with Example 2 of the present invention. The dissolution was conducted at pH 1.2 as described in Example 9.
  • Fig. 2 is a graphical representation of dissolution testing results of a mesalamine formulation prepared in accordance with Example 2 of the present invention. The dissolution was conducted at pH 4.5 as described in Example 9.
  • Fig. 4 is a graphical representation of dissolution testing results of a mesal amine formulation prepared in accordance with Example 2 of the present invention. The dissolution was conducted at pH 7.5 as described in Example 10.
  • Fig. 5 is a graphical representation of dissolution testing results of a mesalamine formulation prepared in accordance with Example 2 of the present invention. The dissolution was conducted at pH 1.2 for two hours followed by 6.8 as described in Example 11.
  • Fig. 6 is a graphical representation of dissolution testing results of a mesalamine formulation prepared in accordance with Example 2 A of the present invention. The dissolution was conducted at pH 1.2 as described in Example 9.
  • Fig. 7 is a graphical representation of dissolution testing results of a mesalamine formulation prepared in accordance with 2A of the present invention. The dissolution was conducted at pH 6.8 as described in Example 9. DETAILED DESCRIPTION QF THE INVENTION Definitions
  • the terms “formulation” and “composition” are used interchangeably and refer to a mixture of two or more compounds, elements, or molecules. In some aspects the terms “formulation” and “composition” may be used to refer to a mixture of one or more active agents with a carrier or other excipients.
  • active agent biological active agent
  • pharmaceutically active agent pharmaceutically active agent
  • pharmaceutically may be used interchangeably to refer to an agent or substance that has measurable specified or selected physiologic activity when administered to a subject in a significant or effective amount. It is to be understood that the term “drag” is expressly encompassed by the present definition as many drugs and prodrugs are known to have specific physiologic activities. These terms of art are well-known in the pharmaceutical, and medicinal aits.
  • mealamine refers to a compound known by the IUPAC name of 5-amino-2-hydroxybenzoic acid and having the structure:
  • Mesalamine has a CAS Registry no. of 89-57-6, and is contained in the Merck Index as monograph no. 5931 (2005), which is incorporated herein by reference.
  • the term "mesalamine compound” may also be used from time to time herein to refer to not only mesalamine, but also to encompass related compounds, such as analogs and homologs thereof, salts, such as acid addition salts thereof, prodrugs, isomers and metabolites thereof, as well as mixtures thereof as dictated by the context of its use.
  • the specific technical name of each compound or molecule will be used, or the group will be specifically named, such as “mesalamine salts”.
  • any of the aforementioned mesalamine compounds or mixtures thereof may be used in combination with any of the other embodiments described herein.
  • subject refers to a mammal that may benefit from the administration of a drug composition or method of this invention.
  • subjects include humans, and may also include other animals such as horses, pigs, cattle, dogs, cats, rabbits, and aquatic mammals.
  • oral dosage form refers to a formulation that is ready for administration to a subject through the oral route of administration.
  • oral dosage forms include without limitation, tablets, capsules, caplets, powders, pellets, granules, etc.
  • Such formulations also include multilayered tablets wherein a given layer may represent a different drug.
  • powders, pellets, and granules may be coated with a suitable polymer or a conventional coating material to achieve, for example, greater stability in the gastrointestinal tract, or to achieve the desired rate of release.
  • capsules containing a powder, pellets or granules may be further coated. Tablets and caplets may be scored to facilitate division of dosing.
  • the dosage forms of the present invention may be unit dosage forms wherein the dosage form is intended to deliver one therapeutic dose per administration. Particular embodiments or groups of embodiments may be expressly limited to subsets of these dosage forms.
  • "sachet" refers to a small, sealed packet containing a quantity of material, which is typically a single-use quantity.
  • an "effective amount” or a “therapeutically effective amount” of a drug refers to a non-toxic, but sufficient amount of the drug, to achieve therapeutic results in treating a condition for which the drug is known to be effective. It is understood that various biological factors may affect the ability of a substance to perform its intended task. Therefore, an "effective amount” or a “therapeutically effective amount” may be dependent in some instances on such biological factors. Further, while the achievement of therapeutic effects may be measured by a physician or other qualified medical personnel using evaluations known in the art, it is recognized that individual variation and response to treatments may make the achievement of therapeutic effects a somewhat subjective decision. The determination of an effective amount is well within the ordinary skill in the art of pharmaceutical sciences and medicine.
  • pharmaceutically acceptable carrier and “carrier” may be used interchangeably, and refer to any inert and pharmaceutically acceptable material that has substantially no biological activity, and makes up a substantial part of the formulation.
  • admixed means that the drug and/or other ingredients can be dissolved, dispersed, or suspended in the carrier. In some cases, the drug may be uniformly admixed in the carrier.
  • the term “substantially” refers to the complete or nearly complete extent or degree of an action, characteristic, property, state, structure, item, or result.
  • an object that is “substantially” enclosed would mean that the object is either completely enclosed or nearly completely enclosed.
  • the exact allowable degree of deviation from absolute completeness may in some cases depend on the specific context. However, generally speaking the nearness of completion will be so as to have the same overall result as if absolute and total completion were obtained.
  • the use of “substantially” is equally applicable when used in a negative connotation to refer to the complete or near complete lack of an action, characteristic, property, state, structure, item, or result.
  • modified release refers to the drug release that is different from an immediate release. Typically, in an immediate release dosage form, about more than 80% of the drug is released from the dosage form in vitro within about 2 hrs. This release may be measured in terms of dissolution of the drug in the dissolution medium.
  • the release is measured under USP conditions, i.e., where the pH is maintained at 1.2 for 2 hours, followed by a pH of 6.8 for the rest of the time. In another aspect, the release is measured at a pH of 1.2 for the entire period of measurement.
  • USP conditions i.e., where the pH is maintained at 1.2 for 2 hours, followed by a pH of 6.8 for the rest of the time.
  • the release is measured at a pH of 1.2 for the entire period of measurement.
  • Other conditions suitable for measurement of modified release are described herein. Examples of such modified release include sustained release, slow- release, delayed-release, pulsatile release etc., which terms are generally known in the art and to the extent they mean a release other than an immediate release.
  • the term "about” is used to provide flexibility to a numerical range endpoint by providing that a given value may be "a little above” or "a little below” the endpoint.
  • the present invention provides modified release mesalamine compound containing dosage forms with certain desirable in vitro dissolution properties and in vivo characteristics.
  • the invention provides methods for formulating a modified release mesalamine capsule dosage form.
  • the capsule may contain one or more cores, depending on the dosage the capsule is intended to deliver, that comprise mesalamine and some excipients that are commonly known in the pharmaceutical industry. These cores are then coated with a specific mixture of polymers comprising a water- impermeable coating polymer and a water-swell able polymer. It has been discovered by the present inventors that this specific mixture of polymers provides the desired product with the desired in vitro and in vivo performance.
  • the cores may be prepared by the following process. Mesalamine and inert pharmaceutically acceptable excipients may be mixed thoroughly to achieve a substantially homogenous mixture.
  • excipients which may be employed are well known to those skilled in the art and include any conventional pharmaceutically acceptable tabletting excipients.
  • suitable excipients include but are not limited to microcrystalline cellulose, dibasic calcium phosphate dihydrate, starch, sodium starch glycolate, crospovidone, croscarmellose sodium, magnesium stearate, lactose, maleic acid, colloidal silicon dioxide, talc, and glyceryl behenate.
  • any of the aforementioned excipients or mixtures thereof may be used in combination with any of the other embodiments described herein.
  • the mixing of the excipients and mesalamine can be accomplished by using high shear granulators (mixers, blenders, etc).
  • the homogenous mixture may be then processed into cores by a number of alternative processes such as granulation, spheronization, spheronization/extrusion, etc. These cores are then optionally dried.
  • the drying process may provide certain advantages such content uniformity, ease of handling, etc.
  • the mesalamine and excipient mixture may be granulated with a water-impermeable polymeric dispersion to form granules of drag + excipient + water-impermeable polymer.
  • the water impermeable polymer may be in one aspect ethylcellulose.
  • the water impermeable polymer may be used at an amount ranging from about 1-20% in a non-aqueous solvent such as ethanol, isopropanol, or a mixture thereof.
  • the water impermeable polymer amount may have the following ranges: from about 1-10%; from about 5-15%; from about 5-10%; from about 3-8%; from about 4-7% of the composition.
  • the water impermeable polymer comprises about 6% of the composition. The amounts described herein are based on a w/w%.
  • This drug + excipient + water-impermeable polymer granulate is then optionally dried to substantially remove any residual solvents. Then the granulates may be optionally wetted to facilitate spheronization to extrude granules into an extruder.
  • the operating conditions of the spheronization and extrusion processes and equipment are generally well-known in the art.
  • the spheronization process yields cores that may be optionally sieved to optimize desired core size.
  • the cores thus obtained by either of the above alternate processes may then be coated with a specific mixture of polymers comprising a water- impermeable coating polymer, a water- swellable polymer or a mixture thereof. The coating substantially completely surrounds the core.
  • water-impermeable polymers include: ethyl cellulose, propyl cellulose, etc.
  • water-swellab ⁇ e polymers include: hydroxypropylmethylcellulose, gums, alginates, etc.
  • the water-swellable polymer may be a pH-dependent- release polymer such as: anionic polymers of methacrylic acid and methacrylates with a dissolution from pH 5.5 and above (such as those commercially known as Eudragit L-100 or Eudragit L 30 D-55); anionic polymer of methacrylic acid and methacrylates with dissolution from pH 6.0 to 7.5 (such as those commercially known as Eudragit LlOO and Eudragit S 100); and copolymer of methacrylic acid, methacrylate and methylmethacrylate with dissolution from pH 7.0 (such as those commercially known as Eudragit FS 30 D).
  • anionic polymers of methacrylic acid and methacrylates with a dissolution from pH 5.5 and above such as those
  • water-swellable polymers are particularly useful in preparation of coatings which facilitate release of active agents, such as mesalamine, at certain stages of the intestinal system, with anionic polymers that dissolve at acid- to-neutral pH facilitating release early in the small intestine, and anionic polymers that dissolve at more alkaline pH facilitating release late in the small intestine or in the colon.
  • this invention contemplates mesalamine granules coated with anionic polymers which dissolve at neutral ⁇ to-alkaline pH. Such granules may be pressed into tablets, preferably in combination with cushioning agent, and these tablets may then be coated with an enteric coating to prevent release of the granules in the stomach.
  • the coating mixture comprises HPMC and ethylcellulose dispersed in an aqueous or substantially nonaqueous solvent.
  • a substantially nonaqueous solvent may be selected form a variety of solvents such as methanol, ethanol, isopropanol, acetone, or a mixture thereof.
  • the HPMC and ethylcellulose may be selected from one of several grades that are commercially available, as described elsewhere in this application.
  • the amount of water-insoluble polymer in the coating may range from about 0.5% to about 10% of the modified release formulation.
  • the amount of water-insoluble polymer in the coating may range as following: from about 1-10%; from about 2-8%; from about 2-6%; from about 1-5%; from about 1-3%; from about 2-3% of the modified release composition. In some specific aspects, the water- insoluble polymer in the coating may amount to about 2.5% of the modified release composition. These amounts are expressed as w/w%.
  • the amount of water-swellable polymer in the coating may range from about 0.1% to about 5% of the modified release formulation. In some aspects, the amount of water-swellable polymer in the coating may range as following: from about 0.5% to about 3%; from about 0.5% to about 2%; from about 0.5% to about 1.5% of the modified release composition. In some specific aspects, the water-swellable polymer in the coating may amount to about 1% of the modified release composition. These amounts are expressed as w/w%. Any of the aforementioned amounts may be used in combination with any of the other embodiments described herein. [0063] in one aspect, the ratio of water-insoluble polymer to the water-swellable polymer may be from about 80 to about 20.
  • That ratio may be: from about 70 to about 30; from about 60 to about 40; from about 50 to about 50; from about 40 to about 60; from about 30 to 70; from about 20 to about SO. Any of the aforementioned ratios may be used in combination with any of the other embodiments described herein.
  • the polymeric coating layer may be accomplished by directly applying the coating polymer mixture alone or together with a binder, either as a solution or as a powder.
  • the binder may be provided as a solution or as a dispersion and may be applied just prior to, or together with the polymer mixture.
  • the polymer mixture may be applied as a dispersion (which may be a solution, suspension or as an emulsion) if the binder is provided as a solution or as a powder.
  • the binder may be provided as a fine powder and the polymer mixture may be provided as a dispersion.
  • the binder powder may become a solution or suspension which then forms a binding film on the cores and thus facilitate the coating of the polymer onto the cores.
  • the polymeric coating layer may be applied to the core according to methods generally known in the art. For example, a two-step process, within which the steps may be repeated a sufficient number of times as necessary to build the thickness of the polymeric coating layer to achieve the desired in vitro and in vivo characteristics.
  • the core is wet with the binder dispersion which serves to adhere the powdered polymeric coating particles to the wet core.
  • Suitable binder dispersions may include conventional pharmaceutically acceptable binder agents solubilized in a suitable solvent.
  • binder agents include but are not limited to vinyl polymers, such as polyvinylpyrrolidone, polyvinyl alcohol, and the like; cellulosic polymers, such as HPMC, HEC, HPC, and the like; acrylic polymers and copolymers such as methacrylic acid copolymers, ethyl acrylate-rnethylmethacrylate copolymers, and the like; natural or synthetic gums, such as guar gum, arabic gum, xanthan gum, and the like; proteins or carbohydrates, such as gelatin, pectin, and the like; and mixtures thereof.
  • polyvinylpyrrolidone is the preferred binder agent. Any of the aforementioned binders or mixtures thereof may be used in combination with any of the other embodiments described herein.
  • Suitable solvents for solubilizing the binder agents include solvents which are capable of substantially completely solubilizing the specific binder agent(s) selected and which are pharmaceutically and biologically acceptable for ingestion. Suitable solvents will be readily determinable by those skilled in the art. Water is currently the preferred solvent for solubilizing the binder agent. However, other examples of suitable solvents will be appreciated by those skilled in the art and are contemplated by the methods of the present invention. Suitable solvents or mixtures thereof may be used in combination with any of the other embodiments described herein. [0067] The binder solution should be of sufficient viscosity to enable the wetting of the cores by any suitable wetting technique known to those skilled in the art.
  • the cores may be wetted with the binder solution by rotating the cores in a bath containing the binder solution.
  • the cores may be suitably wetted by manual application of the binder dispersion by layer the binder solution over the cores as the cores are rotating in a conventional coating pan.
  • the cores may be wetted by spraying the binder dispersion on the cores.
  • the wetting step is advantageously carried out using conventional automated pan coating equipment wherein the cores are sprayed with the binder dispersion while rotating in the pan.
  • the wetted cores may be coated with dry, powdered polymeric coating particles which adhere to the binder-wetted core due to the presence of the binder on the surface of the core.
  • the polymeric coating mixture may be comprised of any suitable water- impermeable, or water-swellable polymers or mixtures thereof known to those skilled in the art; particularly those polymers described herein.
  • suitable polymers include: cellulosic polymers, such as methylcellulose (MC), carboxymethylcellulose (CMC), hydroxypropylcellulose (HPC), hydroxylpropylmethylcellulose (HPMC), hydroxyethykellulose (HEC), and the like; vinyl polymers, such as polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), and the like; acrylic polymers and copolymers, such as acrylic acid polymer, methacrylic acid copolymers, ethyl acrylate-methyl methacrylate copolymers, and the like; and mixtures thereof.
  • cellulosic polymers such as methylcellulose (MC), carboxymethylcellulose (CMC), hydroxypropylcellulose (HPC), hydroxylpropylmethylcellulose (HPMC), hydroxyeth
  • the preferred polymers include ethylcellulose and HPMC. Any of the aforementioned polymers or mixtures thereof may be used in combination with any of the other embodiments described herein.
  • the amount of polymers in the polymeric coating mixture may range from about 0.5% to about 15% of the dispersion. In some aspects, the range may be as following: from about 1-10%; from about 2-8%; from about 2-6%; from about 1-5%; from about 3-5%; from about 4-5%. In some specific aspects, the polymers in the polymeric coating mixture comprise about 4.5%. The amounts described herein are w/w%.
  • HPMC may comprise material of certain viscosity and molecular weight or alternately may comprise mixtures or blends of two or more different forms of HPMC.
  • the mixture may comprise of HPMC having differing molecular weights and solubility characteristics.
  • the mixture may comprise of: a) HPMC having i) a typical weight percent substitution corresponding to about 30% methoxyl and about 10% hydroxypropoxyl groups, and ii) a nominal viscosity of about 2% watery solution at 20 C ranging from about 5 to about 100 mPa.s (e.g., METHOCEL E5); and b) HPMC having i) a typical weight percent substitution corresponding to about 20% methyoxyl and about 8% hydroxypropoxyl groups, and ii) a nominal viscosity of about 2% watery solution at 20 C ranging from about 4,000 to about 100,000 mPa.s (e.g., METHOCEL K15M).
  • HPMC having i) a typical weight percent substitution corresponding to about 30% methoxyl and about 10% hydroxypropoxyl groups, and ii) a nominal viscosity of about 2% watery solution at 20 C ranging from about 5 to about 100 mPa.s (e.g., METH
  • HPMC as used herein, including the claims, refers to either a single HPMC or a blend of two or more forms of the polymer.
  • the swellable polymeric coating layer may be comprising of other substances which are functional equivalents to HPMC.
  • polysaccharides such as gelatin, saccharose, sorbitol, mannanes, and jaluronic acid; polyaminoacids; polyalcohols; polyglycols may also work. Any of the aforementioned substances or mixtures thereof may be used in combination with any of the other embodiments described herein.
  • the polymeric coating layer may also include other excipients such as lubricants, flow promoting agents, plasticizers, antisticking agents, natural and synthetic flavorings and natural and synthetic colorants.
  • additional excipients include polyethylene glycol, polyvinylpyrrolidone, talc, magnesium stearate, glyceryl behenate, stearic acid, and titanium dioxide. Any of the aforementioned excipients or mixtures thereof may be used in combination with any of the other embodiments described herein.
  • the process may be repeated one or more additional times in order to build the thickness of the polymeric coating layer around the core.
  • the number of repetitions is dependent upon the desired predetermined in vitro dissolution profile and in vivo performance.
  • a sufficient number of coating cycles are performed so as to produce a corexoating layer weight ratio of between about 40: 1 and about 1:5 inclusive, or a thickness in excess of about 10 microns ( ⁇ m), and up to about 500 ⁇ m.
  • a sufficient number of coating cycles are completed so as to produce a corexoating layer weight ratio of between about 5: 1 and about 1:3 inclusive, or a thickness of about 50 ⁇ m and about 200-400 ⁇ m.
  • mesalamine may be combined with other drug(s).
  • mesalamine may be combined with the other drug(s) and then coated to form a combination core comprising mesalamine and the other drug(s) in accordance with the procedures described herein.
  • mesalamine cores and cores of the other drug(s) may be formed and coated separately, and then combined. The coated cores of either of these embodiments may then be processed into any of the dosage forms described herein through any of the methods described herein.
  • mesalamine with other drugs used to treat other GI track ailments such as dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease and Zollinger-EUison syndrome.
  • drugs include, e.g., omeprazole, pentaprazole, esemoprazole, and balsalazide, etc.
  • Cushioning agents are agents that provide flexibility to coated mesalamine cores such that when compressed into a tablet, the coated mesalamine cores substantially retain their structural integrity and do not rupture in a significant way. Stated differently, the presence of cushioning agents prevent or minimize the rupture of the coating surrounding the coated mesalamine cores such that no more than about 5% to about 25% of the coated mesalamine leaks out of the formulation prior to its reaching the intended target of action.
  • Examples of cushioning agents include: waxes, fats, lipids, polyoxyethylenes, celluloses and gums, among others, or other flexible materials that are used in pharmaceutical formulations.
  • waxes include; carnuba wax, bees wax, sperm whale wax, candelilla wax, etc.
  • Examples of fats and lipids include: lecithin, hydrogenated vegetable oils, including hydrogenated castor oil, hydrogenated sesame oil, etc.
  • Examples of gums include: gum Arabica, xanthan gum, gum Accacia, etc.
  • Examples of celluloses include: microcrystalline cellulose, lactose, and corn starch.
  • these materials are formed into particles or granules of suitable size, such as ranging from about 50 microns to about 1200 microns.
  • the cushioning particles or granules may range from about 5% to about 95% by weight of the mixture comprising cushioning agents and the coated mesalamine cores,
  • any of the aforementioned cushioning agents or mixtures thereof may be used in combination with any of the other embodiments described herein, and especially when tableting any of the granules described herein.
  • the present invention provides modified release formulations of mesalamine that are suitable for oral administration and delivery in the gastro-intestinal tract.
  • a typical formulation includes: (a) a core comprising mesalamine , and (b) a polymeric coating layer substantially surrounding the core comprising a mixture of water- impermeable polymer and a water-swellable polymer.
  • the polymeric coating layer is applied with or without a binder solution or dispersion. The coating cycle may be repeated one or more times to obtain the necessary coating thickness and other criteria to provide the desired in vitro and in vivo characteristics.
  • the formulations of the present invention may be provided in the form of capsules wherein the core of the present invention is used to fill in a conventional hard or soft-gelatin capsule. Encapsulation within a soft-gelatin capsule is also achievable with conventional techniques. Alternatively, the present formulations may be presented to a patient in the form of a tablet, or a sachet comprising smaller units for swallowing in one or multiple divided doses. [0082] Additionally, the present invention also provides methods of achieving desired therapeutic benefit from mesalamine therapy by administering to the patient the oral dosage form prepared according to the presently disclosed methods. Suitable patient populations for which the methods of the present invention are directed include mammals in general, and in particular, humans.
  • Example IA - Granulation [0085J Pass Mesalamine through a ASTM #30 mesh. Mix Mesalamine (500mg) and Talc (lOmg). Dissolve ethylcellulose in a sufficient amount of Isopropyl alcohol to make 2.75% solution. Drug load Mesalamine onto non pareil sugar beads (139.18mg) with ethyl cellulose (75.45mg) solution. Sugar beads of size #25-30 or #30-35 may be used for this purpose. Drug loading can be done in a rotogranulator with tangential coating or a conventional coating pan with powder spraying/layering or a similar equipment.
  • the mesalamine containing cores are prepared as in Example No.l.
  • the cores containing 500 rng of Mesalamine are coated with the ingredients as in Example 1 using a fluid bed apparatus.
  • a Glatt GPCG 3.1 can be used for this purpose.
  • the mesalamine containing cores are prepared -as in Example No. IA.
  • the cores containing 500 mg of Mesalamine are coated with the ingredients as in Example 1 using a fluid bed apparatus.
  • a Glatt GPCG 3.1 can be used for this purpose.
  • Mesalamine 200rng is used per dosage form which may be prepared similar to Example IA except for the difference in dosage amount and the corresponding differences in the inactive ingredients.
  • Mesalamine 250mg is used per dosage form which may be prepared similar to example IA except for the difference in dosage amount and the corresponding differences in the inactive ingredients.
  • Mesalamine 400mg is used per dosage form which may be prepared similar to example IA except for the difference in dosage amount and the corresponding differences in the inactive ingredients.
  • Example 7 Mesalamine 600mg is used per dosage form which may be prepared similar to example IA except for the difference in dosage amount and the corresponding differences in the inactive ingredients.
  • Example 8
  • Mesalamine 800mg is used per dosage form which may be prepared similar to example IA except for the difference in dosage amount and the corresponding differences in the inactive ingredients.
  • Dissolution testing was conducted according to the official methodology in United States Pharmacoepia 27, monograph titled "Mesalamine Extended Release Capsules," which is incorporated by reference. Briefly, for each test, either one capsule of branded product, Pentasa or one capsule of the present invention (designated as CPI) with 500 mg of equivalent active cores was used. The pH of the medium was maintained at 7.5 with phosphate buffer. 8mL samples were withdrawn at predetermined times using an automated sampler. The Mesalamine concentration in each sample was determined using an UV-Vis spectrophotometer at wavelength of 330nm. The percentage of Mesalamine released over time was calculated and plotted as an average of 6 runs using calibration curves consistent with Beer's law. [0096] Further experimental details are provided as following in Table 5.
  • Example 11 Another indication for the robustness of the formulation as well as for in vivo performance is a measure of the release of the product with the pH of the medium varying over the course of the experiment. Dissolution testing was conducted similar to the official methodology in United States Pharmacoepia 27, as in the monograph titled "Delayed-Release (Enteric coated) Articles - General Drug Release Standard", method A, but using Simulated gastric Fluid without the enzyme Pepsin (pH 1.2) instead of 0.1 N Hydrochloric acid. Briefly, for each test, either one capsule of branded product, Pentasa or one capsule of the present invention (designated as CPI) with 500 mg of equivalent active cores was used.
  • the resulting dissolution data are presented as Table 8, and in graphical form as Figure - 5 for the product of Example IA.
  • the data indicate that the mesalamine modified dosage form as formulated and prepared according to the present invention has acceptable dissolution profile under the varying pH conditions. This result is also found to be quite comparable to the dissolution profile of the branded product, Pentasa, under similar in vitro dissolution conditions. This is also quite an unexpected result.
  • meslamine was loaded on to non-pareil sugar beads and was then coated with a pH-dependent-release coating followed by compression in the presence of cushioning agents. Briefly, the process was as following: Mesalamine and talc were mixed and sieved using a #120 Mesh, Pan RPM was at 45. Drug was loaded on to PG sugar manually using spray guns. Then the drug loaded crystals were dried using Tray dryer at 50 0 C for 4hours.
  • the binder solution was prepared as following: Dissolve Plasdone K29/32 in Isopropyl alcohol continuous stirring. Continue stirring till clear solution is formed.
  • the drug loaded beads were coated with Eudragit SlOO (pH dependent, Methacrylic acid copolymer) using bottom spray technique.
  • the dried coated cores were screened. These were then mixed with cushioning agents, namely, MCCP granules, carnauba wax, Lubritab and PEG 8000 in an approximately 1:3 ratio.
  • the mixture was blended for lOmins by addition of lubricants. Then tabletting was done as per standard protocol.
  • the tablets were then coated with a primary coat of HPMC E5 LV at 2% level, followed by a secondary coat with HPMC phthalate pH dependent polymer at 4.64%, to avoid release of Active in 0.1N HcI.
  • the coated cores were then mixed with cushioning agents and compressed into tablets.
  • the composition of the cushioning agents and the coated cores are given below:

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)

Abstract

L’invention concerne des formulations à libération modifiée ou étendue contenant des composés mésalamine et des procédés associés. Dans certains aspects, des formulations peuvent être sensiblement bioéquivalentes à des formulations de mésalamine approuvée par la FDA telles que PENTASA®.
PCT/US2009/037104 2008-03-14 2009-03-13 Formulations à libération modifiée des médicaments anti-irritabilité WO2009114773A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/049,213 2008-03-14
US12/049,213 US20090017110A1 (en) 2005-05-31 2008-03-14 Modified release formulations of anti-irritability drugs

Publications (2)

Publication Number Publication Date
WO2009114773A2 true WO2009114773A2 (fr) 2009-09-17
WO2009114773A3 WO2009114773A3 (fr) 2010-01-07

Family

ID=41065855

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/037104 WO2009114773A2 (fr) 2008-03-14 2009-03-13 Formulations à libération modifiée des médicaments anti-irritabilité

Country Status (2)

Country Link
US (1) US20090017110A1 (fr)
WO (1) WO2009114773A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20091434A1 (it) * 2009-08-06 2011-02-07 Sofar Spa Composizioni granulari a rilascio controllato di mesalazina e processo per il loro ottenimento.
WO2017084486A1 (fr) * 2015-11-19 2017-05-26 北京罗诺强施医药技术研发中心有限公司 Simple procédé de préparation pour une capacité de charge de médicament préparation à libération prolongée pour traiter la colite et la maladie de crohn
WO2020127539A1 (fr) 2018-12-19 2020-06-25 Cvasthera Utilisation d'un antagoniste de par-1 pour le traitement d'une maladie inflammatoire chronique intestinale

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359812C (fr) 2000-11-20 2004-02-10 The Procter & Gamble Company Formes posologiques pharmaceutiques a couches multiples permettant de reduire l'impact des revetement fractures
US20080069889A1 (en) * 2006-03-07 2008-03-20 Cherukuri S R Compressible resilient granules and formulations prepared therefrom
US20070243248A1 (en) * 2006-04-14 2007-10-18 Cherukuri S Rao Rapidly disintegrating solid oral dosage form of liquid dispersions
CN101431895A (zh) * 2006-05-01 2009-05-13 卡普里康制药公司 新颖的曲坦制剂和制备它们的方法
US20080081072A1 (en) * 2006-09-30 2008-04-03 Cherukuri S R Resin-complex granulation for water-soluble drugs and associated methods
DE102009010091A1 (de) * 2009-02-24 2010-08-26 Beiersdorf Ag Stabilisierte Peelingkapsel
EP2340808A1 (fr) * 2009-12-21 2011-07-06 I.R.B. Istituto Di Ricerche Biotecnologiche S.r.l. Combinaison synergique de phénylpropanoïdes, tels que la verbascoside ou la teupolioside, et la mésalamine
US10071058B2 (en) * 2012-03-07 2018-09-11 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
US20150164920A1 (en) * 2012-03-30 2015-06-18 Laboratorios Del Dr. Esteve S.A. Controlled release formulation comprising mesalamine
US20140099378A1 (en) * 2012-10-10 2014-04-10 Capricorn Pharma Inc. Modified Release Formulations of Anti-Irritability Drugs
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
US20170119680A1 (en) 2015-10-30 2017-05-04 R.P. Scherer Technologies, Llc Extended release film-coated capsules
ITUA20162293A1 (it) 2016-04-05 2017-10-05 Sofar Spa Processo per formulazioni solide di mesalazina

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980173A (en) * 1980-03-20 1990-12-25 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
US5541170A (en) * 1981-07-31 1996-07-30 Tillotts Pharma Ag Orally administrable pharmaceutical compositions
US5855914A (en) * 1988-09-27 1999-01-05 Takeda Chemical Industries, Ltd. Granules having core and their production
US6004581A (en) * 1995-12-21 1999-12-21 Farmaceutisk Laboratorium Ferring A/S Modified release oral pharmaceutical composition and method for the treatment of bowel diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722426D0 (en) * 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
US7737133B2 (en) * 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980173A (en) * 1980-03-20 1990-12-25 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
US5541170A (en) * 1981-07-31 1996-07-30 Tillotts Pharma Ag Orally administrable pharmaceutical compositions
US5855914A (en) * 1988-09-27 1999-01-05 Takeda Chemical Industries, Ltd. Granules having core and their production
US6004581A (en) * 1995-12-21 1999-12-21 Farmaceutisk Laboratorium Ferring A/S Modified release oral pharmaceutical composition and method for the treatment of bowel diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
'Pentasa FDA Official Information Sheet.' DRUGS.COM 2006, page 6 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20091434A1 (it) * 2009-08-06 2011-02-07 Sofar Spa Composizioni granulari a rilascio controllato di mesalazina e processo per il loro ottenimento.
WO2011015964A1 (fr) * 2009-08-06 2011-02-10 Sofar Spa Compositions granulaires à libération contrôlée contenant de la mésalazine et procédé de fabrication associé
US8916201B2 (en) 2009-08-06 2014-12-23 Sofar Spa Controlled-release granular compositions containing mesalazine and process for the manufacture thereof
WO2017084486A1 (fr) * 2015-11-19 2017-05-26 北京罗诺强施医药技术研发中心有限公司 Simple procédé de préparation pour une capacité de charge de médicament préparation à libération prolongée pour traiter la colite et la maladie de crohn
WO2020127539A1 (fr) 2018-12-19 2020-06-25 Cvasthera Utilisation d'un antagoniste de par-1 pour le traitement d'une maladie inflammatoire chronique intestinale
FR3090317A1 (fr) 2018-12-19 2020-06-26 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale

Also Published As

Publication number Publication date
WO2009114773A3 (fr) 2010-01-07
US20090017110A1 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
US20090017110A1 (en) Modified release formulations of anti-irritability drugs
US20070059368A1 (en) Modified release formulations of anti-irritability drugs
JP6815358B2 (ja) 時限パルス放出システム
KR100762847B1 (ko) 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
AU2006297477B2 (en) Pharmaceutical dosage forms having immediate release and/or controlled release properties
KR20070116588A (ko) 약제학적 제형 및 이용 방법
MX2012010361A (es) Composiciones farmaceuticas entericas resistentes al alcohol.
US20050226927A1 (en) Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US20090311317A1 (en) Modified release tolterodine formulations
JP2009536945A (ja) 制御用量薬物送達システム
KR20100059912A (ko) 알리스키렌 및 발사르탄의 제약 조합물
US20070082051A1 (en) Modified Release Formulations of Antihypertensive Drugs
AU2013299938A1 (en) Extended-release levetiracetam and method of preparation
WO2011098194A2 (fr) Mini-pastilles pharmaceutiques destinées à la libération prolongée d'acétate de flécaïnide
US20050220873A1 (en) Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
CA3160862A1 (fr) Forme posologique a utiliser dans le traitement ou la prevention d'une maladie
US20090136550A1 (en) Modified release formulations of diltiazem
TW200536523A (en) Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a gabab receptor agonist
WO2004024128A2 (fr) Composition pharmaceutique a liberation modifiee
US20090130208A1 (en) Modified release niacin formulations
US20140099378A1 (en) Modified Release Formulations of Anti-Irritability Drugs
US20050220874A1 (en) Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist
US20050220863A1 (en) Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
EP2298290A1 (fr) Composition de libération contrôlée comprenant du lévétiracetam
CA3226799A1 (fr) Composition pharmaceutique multiparticulaire

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09721075

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09721075

Country of ref document: EP

Kind code of ref document: A2